Application 213092
- Type
- NDA
- Sponsor
- SUN PHARM INDS INC
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | LENVATINIB | LENVATINIB | CAPSULE; ORAL | 4MG | No | No |
| 002 | LENVATINIB | LENVATINIB | CAPSULE; ORAL | 10MG | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Lenvima | LENVATINIB | Eisai Inc. | f4bedd21-efde-44c6-9d9c-b48b78d7ed1e | 2026-06-30 | Warnings, Adverse reactions | LENVATINIB |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents#
| Document | Submission type | Date |
|---|---|---|
| 71705 | ORIG | 2022-08-03 |